Trial Profile
Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Busulfan; Filgrastim
- Indications Myelofibrosis
- Focus Adverse reactions
- 11 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 16 Jun 2015 New trial record